Recent News

• 06.02.2026 - Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
• 06.02.2026 - Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
• 05.22.2026 - Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
• 05.07.2026 - Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
• 04.27.2026 - Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 8-K Current report
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.04.2026 - 144 Report of proposed sale of securities
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - DEF 14A Other definitive proxy statements